VNDA Vanda Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VNDA

Price (delayed)

$4.63

Market cap

$266.4M

P/E Ratio

115.75

Dividend/share

N/A

EPS

$0.04

Enterprise value

$137.58M

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.

Highlights
VNDA's debt is down by 21% year-on-year and by 6% since the previous quarter
Vanda Pharmaceuticals's equity has increased by 3.4% YoY
VNDA's P/E is 166% above its last 4 quarters average of 43.5
The company's EPS has shrunk by 81% QoQ and by 64% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.vandapharma.com
Peers: BMY LLY JNJ NVS

Key stats

What are the main financial stats of VNDA
Market
Shares outstanding
57.54M
Market cap
$266.4M
Enterprise value
$137.58M
Valuations
Price to earnings (P/E)
115.75
Price to book (P/B)
0.49
Price to sales (P/S)
1.38
EV/EBIT
21.7
EV/EBITDA
14.72
EV/Sales
0.71
Earnings
Revenue
$192.64M
EBIT
$6.34M
EBITDA
$9.35M
Free cash flow
$12.42M
Per share
EPS
$0.04
Free cash flow per share
$0.22
Book value per share
$9.47
Revenue per share
$3.36
TBVPS
$9.19
Balance sheet
Total assets
$648.44M
Total liabilities
$103.53M
Debt
$7.01M
Equity
$544.91M
Working capital
$345.25M
Liquidity
Debt to equity
0.01
Current ratio
4.94
Quick ratio
4.82
Net debt/EBITDA
-13.78
Margins
EBITDA margin
4.9%
Gross margin
92.3%
Net margin
1.3%
Operating margin
-7.2%
Efficiency
Return on assets
0.4%
Return on equity
0.5%
Return on invested capital
2%
Return on capital employed
1.1%
Return on sales
3.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VNDA stock price

How has the Vanda Pharmaceuticals stock price performed over time
Intraday
-3.54%
1 week
14.32%
1 month
19.02%
1 year
-27.09%
YTD
9.72%
QTD
12.65%

Financial performance

How have Vanda Pharmaceuticals's revenue and profit performed over time
Revenue
$192.64M
Gross profit
$177.84M
Operating income
-$13.95M
Net income
$2.51M
Gross margin
92.3%
Net margin
1.3%
VNDA's net income has dropped by 79% since the previous quarter and by 60% year-on-year
VNDA's net margin has dropped by 77% since the previous quarter and by 48% year-on-year
The revenue has decreased by 24% YoY and by 9% QoQ
The gross profit has decreased by 23% YoY and by 8% from the previous quarter

Growth

What is Vanda Pharmaceuticals's growth rate over time

Valuation

What is Vanda Pharmaceuticals stock price valuation
P/E
115.75
P/B
0.49
P/S
1.38
EV/EBIT
21.7
EV/EBITDA
14.72
EV/Sales
0.71
VNDA's P/E is 166% above its last 4 quarters average of 43.5
The company's EPS has shrunk by 81% QoQ and by 64% YoY
VNDA's P/B is 65% below its 5-year quarterly average of 1.4 and 18% below its last 4 quarters average of 0.6
Vanda Pharmaceuticals's equity has increased by 3.4% YoY
VNDA's P/S is 47% below its 5-year quarterly average of 2.6
The revenue has decreased by 24% YoY and by 9% QoQ

Efficiency

How efficient is Vanda Pharmaceuticals business performance
Vanda Pharmaceuticals's ROA has plunged by 78% from the previous quarter and by 60% YoY
Vanda Pharmaceuticals's return on equity has shrunk by 77% QoQ and by 58% YoY
Vanda Pharmaceuticals's ROIC has plunged by 62% from the previous quarter and by 23% YoY
The company's return on sales has shrunk by 60% QoQ and by 25% YoY

Dividends

What is VNDA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VNDA.

Financial health

How did Vanda Pharmaceuticals financials performed over time
The current ratio is down by 22% since the previous quarter and by 13% year-on-year
VNDA's quick ratio is down by 21% from the previous quarter and by 12% YoY
VNDA's debt is 99% smaller than its equity
Vanda Pharmaceuticals's debt to equity has plunged by 50% YoY
VNDA's debt is down by 21% year-on-year and by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.